Table 2.

Systemic and local adverse events

		Gam-COVID-Vac			Gam-COVID-Vac-Lyo
		rAd26-S (n=9)	rAd5-S (n=9)	rAd26-S plus rAd5-S (n=20)	rAd26-S (n=9)	rAd5-S (n=9)	rAd26-S plus rAd5-S (n=20)
Systemic reactions
Hyperthermia
	Mild (37·0–38·4°C; grade 1)	8 (89%)	2 (22%)	19 (95%)	1 (11%)	1 (11%)	6 (30%)
	Moderate (38·5–38·9°C; grade 2)	0	1 (11%)	1 (5%)	0	0	1 (5%)
Headache
	Mild (grade 1)	6 (67%)	3 (33%)	9 (45%)	3 (33%)	4 (44%)	5 (25%)
	Moderate (grade 2)	0	0	2 (10%)	0	0	0
Asthenia
	Mild (grade 1)	3 (33%)	3 (33%)	11 (55%)	0	0	4 (20%)
Muscle and joint pain
	Mild (grade 1)	3 (33%)	2 (22%)	4 (20%)	1 (11%)	2 (22%)	4 (20%)
	Moderate (grade 2)	0	0	1 (5%)	0	0	2 (10%)
Heartbeat (subjective palpitation)
	Mild (grade 1)	3 (33%)	1 (11%)	0	0	0	0
Diarrhoea
	Mild (grade 1)	1 (11%)	0	3 (15%)	0	0	0
Rhinorrhoea
	Mild (grade 1)	0	0	4 (20%)	0	0	0
Loss of appetite
	Mild (grade 1)	2 (22%)	0	1 (5%)	0	0	0
Pain in the oropharynx (pharyngalgia)
	Mild (grade 1)	0	1 (11%)	1 (5%)	0	0	0
Malaise
	Mild (grade 1)	0	0	2 (10%)	0	0	0
Sore throat (throat irritation)
	Mild (grade 1)	0	0	2 (10%)	0	0	0
Hives
	Mild (grade 1)	1 (11%)	0	0	0	0	0
Nasal congestion
	Mild (grade 1)	0	0	1 (5%)	0	0	0
Cough
	Mild (grade 1)	0	0	1 (5%)	0	0	0
Sneezing
	Mild (grade 1)	0	0	1 (5%)	0	0	0
Changes in laboratory variables
	Mild (grade 1)	9 (100%)	8 (89%)	20 (100%)	7 (78%)	6 (67%)	18 (90%)
	Moderate (grade 2)	0	1 (11%)	0	0	0	0
Local reactions
Pain
	Mild (grade 1)	7 (78%)	5 (56%)	8 (40%)	5 (56%)	7 (78%)	12 (60%)
Oedema
	Mild (grade 1)	0	0	0	2 (22%)	1 (11%)	0
Hyperthermia
	Mild (grade 1)	0	0	2 (10%)	0	1 (11%)	0
Itch
	Mild (grade 1)	1 (11%)	0	0	0	0	0
Swelling
	Mild (grade 1)	0	0	1 (5%)	0	0	0

The table shows the total number (%) of volunteers who developed adverse events, according to severity (mild [grade 1], moderate [grade 2], and severe [grade 3]). No grade 3 adverse events were reported. Some volunteers had adverse events of two degrees of severity. Gam-COVID-Vac=frozen vaccine formulation. Gam-COVID-Vac-Lyo=lyophilised vaccine formulation. rAd26-S=recombinant adenovirus type 26 carrying the gene for SARS-CoV-2 full-length glycoprotein S. rAd5-S=recombinant adenovirus type 5 carrying the gene for SARS-CoV-2 full-length glycoprotein S. SARS-CoV-2=severe acute respiratory syndrome coronavirus 2.